Vivus (VVUS) Target Lowered to $14 from $20 at Piper

September 12, 2013 9:16 AM EDT
Get Alerts VVUS Hot Sheet
Price: $1.16 --0%

Rating Summary:
    4 Buy, 8 Hold, 5 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 29 | Down: 30 | New: 23
Trade VVUS Now!
Join SI Premium – FREE
Piper Jaffray maintained an Overweight rating on Vivus (NASDAQ: VVUS) and cut its price target to $14.00 (from $20.00). Analyst Charles Duncan cited IP concerns regarding key diet drug Qsymia. Duncan's new price target includes lower sales projections based on patent expiration in 2020 vs 2027.

Duncan still thinks Vivus will sign a partner deal by the end of the year. Long term sales projections are intact and sales are likely to accelerate from 2014 to 2016, said the analyst.

For an analyst ratings summary and ratings history on Vivus click here. For more ratings news on Vivus click here.

Shares of Vivus closed at $10.41 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View, Analyst PT Change

Related Entities

Piper Jaffray

Add Your Comment